PRAX-222 - Initial Dose + PRAX-222 - Initial Ascending Doses + PRAX-222 - Optional Ascending Doses + PRAX-222 - Fixed Doses
Phase 1/2Recruiting 0 watching 0 views this week💤 Quiet
38
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
SCN2A-DEE
Conditions
SCN2A-DEE, Epilepsy
Trial Timeline
Apr 13, 2023 → Sep 1, 2027
NCT ID
NCT05737784About PRAX-222 - Initial Dose + PRAX-222 - Initial Ascending Doses + PRAX-222 - Optional Ascending Doses + PRAX-222 - Fixed Doses
PRAX-222 - Initial Dose + PRAX-222 - Initial Ascending Doses + PRAX-222 - Optional Ascending Doses + PRAX-222 - Fixed Doses is a phase 1/2 stage product being developed by Praxis Precision Medicines for SCN2A-DEE. The current trial status is recruiting. This product is registered under clinical trial identifier NCT05737784. Target conditions include SCN2A-DEE, Epilepsy.
Hype Score Breakdown
Clinical
13
Activity
8
Company
7
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05737784 | Phase 1/2 | Recruiting |